Cardiology Today Current Issue
The following articles appeared in the print edition of Cardiology Today.
Table of Contents
- Beyond safety, new diabetes drugs offer CV benefit
-
- Balloon-expandable TAVR system receives FDA indication for use in intermediate-risk patients
- FDA approves MRI-compatible subcutaneous ICD
- FDA approves valve for minimally invasive surgical aortic valve replacement
- FDA denies AstraZeneca request to block approvals of generic rosuvastatin
- FDA does not approve reversal agent for anticoagulation drugs
- HF with recovered ejection fraction underscores importance of reverse remodeling
- AHA: Digital strategies can improve emergency heart, stroke care
- AHA: ‘Sit less, move more’
-
- Betrixaban may reduce VTE risk in certain patients with acute illness
- CAD in men with HIV linked to inflammatory biomarkers
- CDC: Type of job can impact CV health
- CV death decline slowing in US
- FDA commissioner: New technologies boosting CV treatments, but evidence must keep pace
- Financial incentives help low-income adults quit smoking
- Genetic testing helps identify causes of sudden cardiac death in children, young adults
- HF after MI less likely among patients with higher education
-
- INTERSTROKE: Modifiable risk factors may explain nine of 10 acute strokes
- Liraglutide does not improve clinical stability after hospitalization for HFrEF
- Many patients with AF often prescribed aspirin over anticoagulants
- Metabolic syndrome severity may increase before menopause
- Most US children do not meet AHA definition of ideal childhood CV health
- Neurology society opposes routine use of closure devices for patients with PFO, stroke
- Novel device enables surgical mitral valve repair without stopping heart
- Off-site central monitoring applying standardized cardiac telemetry safe, effective
-
- Omega-3 fatty acids may improve cardiac remodeling after acute MI
- PLATFORM: CTA with FFRCT linked to similar results, lower costs vs. usual care at 1 year
- Review: Mobile health holds promise for early diagnosis, prevention of CVD
- Sacubitril/valsartan linked to fewer 30-day readmissions after hospitalization for HF
- Some risk for non-syndromic congenital heart disease inherited from healthy parents
- Statin therapy lowers CAD, mortality risk in familial hypercholesterolemia
- Studies offer conflicting findings on magnesium's effect on BP
- Sudden cardiac death common in male minority athletes
-
- TINSAL-CVD: Salsalate fails to reduce progression of noncalcified coronary plaque volume
- Tree nut consumption linked to lower inflammatory biomarkers
- USPSTF: Data inconclusive on lipid disorder screening for children, teens
- Women lag behind men in lifesaving cardiac arrest treatments
- Working single mothers may have higher risk for CHD, stroke
- CMS announces new initiative for MI, stroke prevention
- CMS proposes new bundled payment models for high-quality cardiac, hip fracture care
- NHLBI working group identifies knowledge gaps on role of microbiota in BP regulation
-
- Phase 2 trial of drug to treat hypertrophic cardiomyopathy to be launched
- Cryoballoon catheter tied to fewer repeat ablations, lower hospitalization rates
- Genetic variants play role in clopidogrel effectiveness after minor stroke, TIA
- Sutureless aortic bioprosthesis safe, feasible in patients requiring surgical AVR
- CV implications of newer obesity medications Anne M. Kome, PharmD; Debra J. Barnette, PharmD; Sarah A. Spinler, PharmD, FCCP, FAHA, FASHP, AACC, BCPS (AQ Cardiology)
- Trial Scorecard: CHANCE-HF
- Trial Scorecard: COBEST
- Trial Scorecard: ENCHANTED
-
- Trial Scorecard: FIGHT
- Trial Scorecard: JACC
- Trial Scorecard: OMEGA-REMODEL
- Trial Scorecard: POST-IT
- Trial Scorecard: TINSAL-CVD